Skip to main content
ROCKET PHARMACEUTICALS, INC. logo

ROCKET PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · RCKT ISIN · US77313F1066 LEI · 549300R7VV82YUIN4Y93 US Manufacturing
Filings indexed 890 across all filing types
Latest filing 2015-02-19 Director's Dealing
Country US United States of America
Listing US RCKT

About ROCKET PHARMACEUTICALS, INC.

https://www.rocketpharma.com/

Rocket Pharmaceuticals, Inc. is a fully integrated, late-stage biotechnology company that develops gene therapies for rare and devastating diseases. The company's mission is to provide cures by correcting the root cause of disease at the genetic level. It utilizes a multi-platform approach, employing both ex vivo lentiviral (LV) and in vivo adeno-associated viral (AAV) technologies. This strategy allows for the selection of the most suitable platform for specific conditions, with a focus on diseases with high unmet needs, including bone marrow-derived and cardiovascular disorders. Rocket aims to advance a sustainable pipeline of first-in-class investigational genetic therapies for patients.

Recent filings

Filing Released Lang Actions
FORM 3/A SUBMISSION
Director's Dealing
2015-02-19 English
FORM 3/A SUBMISSION
Director's Dealing
2015-02-19 English
FORM 3/A SUBMISSION
Director's Dealing
2015-02-19 English
FORM 3 SUBMISSION
Director's Dealing
2015-02-19 English
FWP
Capital/Financing Update Classification · 95% confidence The document is a detailed pricing term sheet for a concurrent offering of common stock and convertible senior notes by Inotek Pharmaceuticals Corporation. It includes specific terms such as number of shares, pricing, underwriting discounts, interest rates, conversion rights, maturity dates, and use of proceeds. The document references registration statements and prospectuses filed with the SEC, and it is filed pursuant to Rule 433, which relates to free writing prospectuses used in securities offerings. The content is focused on capital raising activities, detailing the terms of the stock and notes offerings, underwriting arrangements, and financial terms. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an annual or interim report, earnings release, or regulatory filing unrelated to financing. It is not a report publication announcement since it contains substantive details of the offering terms rather than just announcing a report's availability. Therefore, the correct classification is CAP with high confidence.
2015-02-18 English
Regulatory Filings 2015
Regulatory Filings
2015-02-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.